Reference : A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics ...

	Document type :	Parts of books : Contribution to collective works
	Discipline(s) :	Life sciences : Multidisciplinary, general & others
	Focus Areas :	Systems Biomedicine
	To cite this reference:	http://hdl.handle.net/10993/55623

Title :	A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures
Language :	English
Author, co-author :	Narayanasamy, Shaman [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core >]
	Stroggilos, Rafael [Academy of Athens > Systems Biology Center]
	Balaur, Irina-Afrodita [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core >]
	Vlahou, Antonia [Academy of Athens > Systems Biology Center]
	Mischak, Harald [Mosaiques Diagnostics > Department of Biomarker Research]
	Frantzi, Maria [Mosaiques Diagnostics > Department of Biomarker Research]
Other contributor :	Mokou, Marika [Mosaiques Diagnostics > Department of Biomarker Research]
Publication date :	7-Jul-2023
Main document title :	Methods in Molecular Biology
Editor :	Walker, John
Publisher :	Springer
Peer reviewed :	No
Keywords :	[en] bladder cancer ; urology ; drug discovery ; drug repurposing ; data driven
Abstract :	[en] Delivering better care for patients with bladder cancer (BC) necessitates the development of novel therapeutic strategies that address both the high disease heterogeneity and the limitations of the current therapeutic modalities, such as drug low efficacy and patient resistance acquisition. Drug repurposing is a cost-effective strategy that targets the reuse of existing drugs for new therapeutic purposes. Such a strategy could open new avenues toward more effective BC treatment. BC patients' multi-omics signatures can be used to guide the investigation of existing drugs that show an effective therapeutic potential through drug repurposing. In this book chapter, we present an integrated multilayer approach that includes cross-omics analyses from publicly available transcriptomics and proteomics data derived from BC tissues and cell lines that were investigated for the development of disease-specific signatures. These signatures are subsequently used as input for a signature-based repurposing approach using the Connectivity Map (CMap) tool. We further explain the steps that may be followed to identify and select existing drugs of increased potential for repurposing in BC patients.
Research centres :	Mosaiques Diagnostics
Funders :	Fonds National de la Recherche - FnR ; Eurostars - EUREKA
Name of the research project :	ReDiRECt
Target :	Researchers ; Professionals ; Students ; General public
Permalink :	http://hdl.handle.net/10993/55623
DOI :	10.1007/978-1-0716-3291-8_4
Other URL :	https://pubmed.ncbi.nlm.nih.gov/37410228/
FnR project :	FnR ; FNR14214446 > Reinhard Schneider > ReDiRECt > Molecular -Based, Data -Driven Drug Repurposing For Bladder Cancer > 01/07/2020 > 30/06/2023 > 2020

There is no file associated with this reference.

All documents in ORBi^lu are protected by a user license.

 

University of Luxembourg Library |  Feedback |  Legal notices Site Map